Global Diabetes Pen Market

1 INTRODUCTION OF GLOBAL DIABETES PEN MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DIABETES PEN MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL DIABETES PEN MARKET, BY INDICATION
5.1 Type I diabetes
5.2 Type II diabetes

6 GLOBAL DIABETES PEN MARKET, BY PRODUCT TYPE
6.1 Insulin Pens
6.2 Insulin pen needles

7 GLOBAL DIABETES PEN MARKET, BY TYPE
7.1 Disposable
7.2 Reusable

8 GLOBAL DIABETES PEN MARKET, BY THERAPIE
8.1 Insulin
8.2 Glucagon-like peptide-1
8.3 Growth hormones

9 GLOBAL DIABETES PEN MARKET, BY END USER
9.1 Hospitals
9.2 Clinics
9.3 Home care settings

10 GLOBAL DIABETES PEN MARKET, BY GEOGRAPHY
10.1 Overview
10.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025

11 GLOBAL DIABETES PEN MARKET COMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Astra Zeneca
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 BD
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Eli Lilly and Company
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Biocon
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 Sanofi
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Jiangsu Delfu medical device Co.,Ltd.
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 Owen Mumford Ltd.
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 WOCKHARDT
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Smiths Group plc.
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Developments

12.10 P&B Pharmaceuticals Ltd.
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Developments

12.11 NIPRO Medical Corporation
12.11.1 Overview
12.11.2 Financial Performance
12.11.3 Product Outlook
12.11.4 Key Developments

12.12 Novo Nordisk A/S
12.12.1 Overview
12.12.2 Financial Performance
12.12.3 Product Outlook
12.12.4 Key Developments

12.13 Injex UK
12.13.1 Overview
12.13.2 Financial Performance
12.13.3 Product Outlook
12.13.4 Key Developments

12.14 Mannkind Corporation
12.14.1 Overview
12.14.2 Financial Performance
12.14.3 Product Outlook
12.14.4 Key Developments

13 Appendix
13.1 Related Reports